ClinicalTrials.gg
CompletedNCT02349295SPIRIT-P2Updated Jul 1, 2020Results posted

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis

A Phase 3 interventional study of Placebo and Ixekizumab 80 mg Q4W in Psoriatic Arthritis, sponsored by Eli Lilly and Company. Completed at 109 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-01.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.

Enrollment
64th of 158
363 · median 237
Started
2014
with 9 others
Phase 3
71 of 193
4 open now
Registered
59th of 193
by date
Lead sponsor
5 of 193
Eli Lilly and Company

Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 64th largest by enrollment of the 158 interventional ones that give a count, is one of 10 that started in 2014, is one of 71 in phase 3, and was the 59th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Arthritis, Psoriatic with a site in United States, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate how effective and safe the study drug known as ixekizumab is in participants with active psoriatic arthritis.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presents with established diagnosis of active psoriatic arthritis (PsA) for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
  • Active PsA defined as the presence of at least 3 tender and at least 3 swollen joints
  • Presence of active psoriatic skin lesion or a history of plaque psoriasis (Ps)
  • Men must agree to use a reliable method of or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • Have been treated with 1 or more conventional disease-modifying antirheumatic drugs (cDMARDs)
  • Have had prior treatment with at least 1 and not more than 2 tumor necrosis factor (TNF) inhibitors. The participant must have discontinued at least 1 TNF inhibitor due to either an inadequate response (based on a minimum of 12 weeks on therapy) or documented intolerance.

Exclusion criteria

Exclusion Criteria:

  • Current use of biologic agents for treatment of Ps or PsA
  • Inadequate response to greater than 2 biologic DMARDs
  • Current use of more than one cDMARDs
  • Diagnosis of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
  • Have received treatment with interleukin (IL) -17 or IL12/23 targeted monoclonal antibody (MAb) therapy
  • Serious disorder or illness other than psoriatic arthritis
  • Serious infection within the last 3 months
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
363 participants (actual)

Study arms

  • Experimental
    Ixekizumab 80 milligram (mg) every 2 Weeks (Q2W)

    Blinded Treatment Period (Week(wk) 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22, and 24.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q2W and IR from ixekizumab 80 mg Q2W who continued on ixekizumab 80 mg Q2W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q2W given on Wks 16,18,20,22,24. Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q2W at week 0 and continued on ixe 80 mg Q2W during the Extension Period. Pts who received ixekizumab 80 mg Q2W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).

    Drug: Placebo · Drug: Ixekizumab 80 mg Q2W

  • Experimental
    Ixekizumab 80 mg Q4W

    Blinded Treatment Period (Week 0-24): Participants (pts) received a starting dose of 160 mg of ixekizumab (ixe) given as 2 subcutaneous (SC) injections at Wk 0 followed by 1 SC injection of 80 mg of ixe Q4W given on Wks 4, 8 and 12 alternating with placebo for ixe injections Q4W given on Wks 2,6,10,14,18, and 22.Week 16 inadequate responders (IR) from the placebo treatment group who were re-randomized (1:1) to ixe 80 mg Q4W and IR from ixekizumab 80 mg Q4W who continued on ixekizumab 80 mg Q4W. Pts receive rescue therapy while receiving ixekizumab given as 1 injection of 80 mg Q4W given on Wks 16 and 20 alternating with placebo for ixe injections Q4W given on Wks 18 and 22.Extension Period (Wk24-156):Pts who were randomized to ixe 80 mg Q4W at week 0 and continued on ixe 80 mg Q4W during the Extension Period.Pts who received ixekizumab 80 mg Q4W,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).

    Drug: Placebo · Drug: Ixekizumab 80 mg Q4W

  • Placebo comparator
    Placebo

    Blinded Treatment Period (Wk 0-24): Pts received placebo for Ixe as 2 SC injections followed by 1 SC injection Q2W given on Wks 2,4,6,8,10,12,14,16,18,20,22 and 24. Pts initially randomized to placebo treatment group in the double blind treatment period,flagged as IR at Wk 16,re-randomized to ixe 80 mg Q2W/Q4W for the remainder of the current period and following period. Extended Treatment Period (Wk 24-156): Pts who were randomized to placebo at Week 0 then randomized to ixekizumab 80 mg Q2W/Q4W during the Extension Period.Pts who remained on placebo at the completion of the double blind treatment period received the first dose of ixe (160 mg starting dose) at Wk 24.Pts who were IRs at Wk 16 and were re-randomized to ixe at Wk 16 received the first dose of ixe (160 mg starting dose) at Wk 16. Pts who received placebo,who were either completed the study or discontinued the study early entered the post-treatment follow-up period (12-24 weeks).

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)

    ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

    HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.

    Time frame: Baseline, Week 24

  2. Percentage of Participants Achieving ACR20

    ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 12

  3. Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)

    ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 24

  4. Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)

    ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 24

  5. Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75

    The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.

    Time frame: Week 12

  6. Percentage of Patients Achieving Minimal Disease Activity (MDA)

    It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.

    Time frame: Week 24

  7. Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)

    The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, "0" indicates good score here.

    Time frame: Week 24

  8. Change From Baseline in Itch Numeric Rating Scale (NRS)

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Tender Joint Count (TJC)

    TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  10. Change From Baseline in Swollen Joint Count (SJC)

    SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  11. Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  12. Change From Baseline in Patients Global Assessment of Disease Activity VAS

    The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  13. Change From Baseline in Physicians Global Assessment of Disease Activity VAS

    The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  14. Change From Baseline in C-Reactive Protein (CRP)

    C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  15. Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)

    The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  16. Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score

    The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  17. Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score

    The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  18. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  19. Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

    Time frame: Baseline, Week 24

  20. Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

    Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.

    Time frame: Week 24

  21. Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab

    The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.

    Time frame: All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)

  22. Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab

    The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).

    Time frame: All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)

  23. Percentage of Participants Achieving ACR 20

    ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 52 and Week 156

  24. Percentage of Participants Achieving ACR 50

    ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 52 and Week 156

  25. Percentage of Participants Achieving ACR 70

    ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

    Time frame: Week 52 and Week 156

07

Results

Posted Dec 14, 2017

Participant flow

Double Blind Treatment (Week 0-24)
Participant flow — Double Blind Treatment (Week 0-24)
MilestoneIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Started12312211800000000000
Received atleast one dose of study drug12312211800000000000
Completed1091119400000000000
Not completed14112400000000000
Withdrew: Adverse event75500000000000
Withdrew: Lack of efficacy42900000000000
Withdrew: Withdrawal by subject22700000000000
Withdrew: Lost to follow-up11200000000000
Withdrew: Failure to meet randomization01100000000000
IR (Week 16-24)
Participant flow — IR (Week 16-24)
MilestoneIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Started000171516160000000
Completed000161516160000000
Not completed00010000000000
Withdrew: Lack of efficacy00010000000000
Long-Term Extension Period (Week 24-156)
Participant flow — Long-Term Extension Period (Week 24-156)
MilestoneIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Started00000001071114646000
Completed000000055702023000
Not completed000000052412623000
Withdrew: Lack of efficacy000000032251918000
Withdrew: Adverse event00000009922000
Withdrew: Unknown/missing00000002030000
Withdrew: Death00000001110000
Withdrew: Withdrawal by subject00000004213000
Withdrew: Lost to follow-up00000002200000
Withdrew: Physician decision00000002200000
Follow-Up Period (Up to 12-24 Weeks)
Participant flow — Follow-Up Period (Up to 12-24 Weeks)
MilestoneIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Started0000000000014214517
Completed0000000000013313716
Not completed00000000000981
Withdrew: Withdrawal by subject00000000000151
Withdrew: Lost to follow-up00000000000120
Withdrew: Adverse event00000000000110
Withdrew: Physician decision00000000000200
Withdrew: Unknown/missing00000000000400

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)

ACR20 response is defined as a greater than or equal to (≥) 20% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain visual analog scale (VAS), Participant's Global Assessment of Disease Activity VAS (PatGA), Physician's Global Assessment of the Disease Activity VAS (PGA), Participant's Assessment of Physical Function using the Health Assessment Questionnaire Disability Index (HAQ-DI), or Acute Phase Reactant as measured by high sensitivity C-reactive protein (hs-CRP).

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving American College of Rheumatology 20 Index (ACR20)19.553.348.0
Statistical analysis
  • Placebo vs Ixekizumab 80 mg Q4W · Regression, Logistic · p = <0.001 (model includes: treatment, geographic region, and tumor necrosis factor inhibitor (TNFi) experience (inadequate responder to 1 TNFi, inadequate responder to 2 TNFi, or intolerance to a TNFi).) · Odds ratio (or): 4.74 · 95% CI 2.65 to 8.481) uses a Wald's test , 2) Non-responder imputation (NRI) was used to calculate the response rates.
  • Placebo vs Ixekizumab 80 mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 3.79 · 95% CI 2.12 to 6.78
SecondaryChange From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score

HAQ-DI is a participant reported questionnaire that measures disease-associated disability(physical function).It consists of 24 questions with 8 domains: dressing/grooming,arising,eating,walking,hygiene,reach,grip and other daily activities. The disability section scores the participant's self-perception on degree of difficulty (0=without any difficulty,1=with some difficulty,2=with much difficulty,3=unable to do)covering the 8 domains.The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability.The reported use of special aids/devices and/or the need for assistance of another person to perform these activities is assessed.Least Square (LS) mean calculated using Mixed Model Repeated Measurements (MMRM) analysis with treatment,baseline score,geographic region, TNFi experience,visit, treatment-by-visit interaction(itcn), geographic region-by-visit itcn,TNFi experience-by-visit itcn and baseline score-by-visit itcn.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score
units on a scalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Score-0.2 ± 0.08-0.6 ± 0.07-0.4 ± 0.07
SecondaryPercentage of Participants Achieving ACR20

ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving ACR20
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving ACR2022.050.048.0
SecondaryPercentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)

ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving American College of Rheumatology 50 Index (ACR50)5.135.233.3
SecondaryPercentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)

ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants Achieving American College of Rheumatology 70 Index (ACR70)022.112.2
SecondaryPercentage of Participants With Psoriasis Area and Severity Index (PASI) 75

The PASI is an index that combines assessments of the extent of body-surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of desquamation, erythema, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no psoriasis to 72 for the most severe disease. Participants achieving PASI 75 were defined as having an improvement of at least 75% in the PASI compared to their baseline measures.

Time frame:
Week 12
Reported as:
Number · Percentage of Participants
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 75
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Participants With Psoriasis Area and Severity Index (PASI) 7510.457.461.8
SecondaryPercentage of Patients Achieving Minimal Disease Activity (MDA)

It uses a composite of 7 key outcome measures (includes PASI) used in PsA to encompass all of the domains of the disease to measure the overall state of a patients' disease. The LEI is used to assess tender entheseal points. Patients are classified as achieving MDA if they fulfill 5 of 7 outcome measures: 1. TJC ≤1, 2. SJC ≤1, 3. PASI total score ≤1 or BSA ≤3, 4. patient pain VAS score of ≤15, 5. patient global VAS score of ≤20, 6. HAQ-DI score ≤0.5, 7. tender entheseal points (6 entheseal points) ≤1.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Patients Achieving Minimal Disease Activity (MDA)
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Patients Achieving Minimal Disease Activity (MDA)3.427.923.6
SecondaryPercentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)

The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle, left and right; medial femoral condyle, left and right; Achilles tendon insertion, left and right). Each site was assigned a score of 0 (absent) or 1 (present); the results from each site were then added to produce a total score (range 0 to 6). So, "0" indicates good score here.

Time frame:
Week 24
Reported as:
Number · Percentage of Participants
Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)
Percentage of ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Percentage of Patients Achieving Complete Resolution in Enthesitis as Assessed by the Leeds Enthesitis Index (LEI)21.735.331.0
SecondaryChange From Baseline in Itch Numeric Rating Scale (NRS)

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participants itching from psoriasis was indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Itch Numeric Rating Scale (NRS)
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Itch Numeric Rating Scale (NRS)-0.7 ± 0.40-3.4 ± 0.39-3.3 ± 0.39
SecondaryChange From Baseline in Tender Joint Count (TJC)

TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Tender Joint Count
Change From Baseline in Tender Joint Count (TJC)
Tender Joint CountPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Tender Joint Count (TJC)-6.2 ± 1.96-12.7 ± 1.87-12.5 ± 1.77
SecondaryChange From Baseline in Swollen Joint Count (SJC)

SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Swollen Joint Count
Change From Baseline in Swollen Joint Count (SJC)
Swollen Joint CountPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Swollen Joint Count (SJC)-5.0 ± 1.05-8.5 ± 0.99-7.4 ± 0.94
SecondaryChange From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Participants Assessment of Pain Visual Analog Scale (VAS)-21.4 ± 3.97-36.9 ± 3.74-33.5 ± 3.58
SecondaryChange From Baseline in Patients Global Assessment of Disease Activity VAS

The patient's overall assessment of his or her PsA activity will be recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Patients Global Assessment of Disease Activity VAS
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Patients Global Assessment of Disease Activity VAS-19.0 ± 3.91-40.7 ± 3.68-37.3 ± 3.53
SecondaryChange From Baseline in Physicians Global Assessment of Disease Activity VAS

The investigator will be asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Physicians Global Assessment of Disease Activity VAS
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Physicians Global Assessment of Disease Activity VAS-18.3 ± 3.98-40.0 ± 3.85-37.9 ± 3.75
SecondaryChange From Baseline in C-Reactive Protein (CRP)

C-reactive protein (CRP) is a disease related biomarker and measured in milligrams per liter. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · milligram per liter (mg/L)
Change From Baseline in C-Reactive Protein (CRP)
milligram per liter (mg/L)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in C-Reactive Protein (CRP)-3.6 ± 1.87-11.8 ± 1.76-9.8 ± 1.68
SecondaryChange From Baseline in Disease Activity Score-CRP (DAS28-CRP)

The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in mg/L), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 millimeter (mm) VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)-0.8 ± 0.20-2.1 ± 0.19-1.8 ± 0.18
SecondaryChange From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score

The BASDAI is a self-administered measure used to answer 6 questions with a 0 to 10 centimeter (cm) VAS pertaining to the 5 major symptoms of axial activity. To give each symptom equal weighting, the mean of the 2 scores relating to morning stiffness was taken. The resulting 0 to 50 score was divided by 5 to give a final 0 to 10 BASDAI Score. BASDAI ranges from 0-10. Higher scores represent greater disease activity. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score-2.1 ± 0.38-3.7 ± 0.36-3.6 ± 0.35
SecondaryChange From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score

The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rated their fatigue (feeling tired or worn out) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in Fatigue Severity Numeric Rating Scale (NRS) Score-0.7 ± 0.37-2.0 ± 0.35-2.1 ± 0.34
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Physical Component Summary (PCS)3.3 ± 1.368.9 ± 1.298.2 ± 1.23
SecondaryChange From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean was calculated using MMRM analysis with treatment, baseline score, geographic region, TNFi experience, visit, treatment-by-visit interaction, geographic region-by-visit interaction, TNFi experience-by-visit interaction, and baseline score-by-visit interaction.

Time frame:
Baseline, Week 24
Reported as:
Least squares mean · Units on a Scale
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)
Units on a ScalePlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Change From Baseline in 36-Item Short-Form Health Survey (SF-36) Scores: Mental Component Summary (MCS)0.9 ± 1.323.6 ± 1.244.0 ± 1.18
SecondaryNumber of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)

Number of participants with positive treatment emergent anti-ixekizumab antibodies was summarized by treatment group.

Time frame:
Week 24
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)
ParticipantsPlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Number of Participants With Treatment Emergent Anti-Drug Antibodies (TE-ADA)184
SecondaryPharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab

The Ctrough is the minimum observed serum concentration at steady state of Ixekizumab. The Ctrough at Week 24 was reported.

Time frame:
All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)
Reported as:
Geometric mean · micograms per milliliter (mcg/mL)
Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab
micograms per milliliter (mcg/mL)Ixekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Pharmacokinetics (PK):Minimum Observed Serum Concentration at Steady State (Ctrough,ss) of Ixekizumab2.46 ± 79.17.96 ± 71.1
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab

The AUC(Tau,Steady State) is the area under the concentration-time curve for dosing interval (Tau) at steady state of ixekizumab (Tau is 28 days for 80 mg Q4W cohort, and is 14 days for 80mg Q2W cohort, respectively).

Time frame:
All immunogenicity samples post the first Ixekizumab dose (Week 4, 12, 24, 36, and 52) and PK samples collected per dedicated sparse sampling plan (4-5 samples per patient) across Weeks 1 through 24 and Early termination visit (ETV)
Reported as:
Geometric mean · mcg*day/mL
Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab
mcg*day/mLIxekizumab 80 mg Q4WIxekizumab 80 mg Q2W
Pharmacokinetics: Area Under the Concentration-Time Curve for Dosing Interval (Tau) at Steady State [AUC(Tau,Steady State)] of Ixekizumab141 ± 59.3143 ± 57.5
SecondaryPercentage of Participants Achieving ACR 20

ACR20 response is defined as a ≥20% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 52 and Week 156
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR 20
Percentage of participantsIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment Period
Week 5258.967.650.060.9
Week 15642.150.539.145.7
SecondaryPercentage of Participants Achieving ACR 50

ACR50 response is defined as a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 52 and Week 156
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR 50
Percentage of participantsIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment Period
Week 5238.345.934.843.5
Week 15629.035.126.134.8
SecondaryPercentage of Participants Achieving ACR 70

ACR70 response is defined as a ≥70% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of Joint Pain VAS, Participant's Global Assessment of Disease Activity VAS, Physician's Global Assessment of the Disease Activity VAS, Participant's Assessment of Physical Function using the HAQ-DI, or hs-CRP.

Time frame:
Week 52 and Week 156
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving ACR 70
Percentage of participantsIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment Period
Week 5220.628.815.223.9
Week 15622.421.610.919.6

Adverse events

Collected over Baseline Up To 2.55 Years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment Period—8/123 (6.5%)58/123 (47.2%)
Ixekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment Period—3/122 (2.5%)58/122 (47.5%)
Placebo (PBO) - Blinded Treatment Period—4/118 (3.4%)40/118 (33.9%)
Ixe 80 mg Q2W - Blinded Treatment Period IR—0/17 (0%)5/17 (29.4%)
Ixe 80 mg Q4W - Blinded Treatment Period IR—0/15 (0%)8/15 (53.3%)
PBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IR—0/16 (0%)11/16 (68.8%)
PBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IR—1/16 (6.3%)8/16 (50%)
Ixe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment Period—10/107 (9.3%)59/107 (55.1%)
Ixe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment Period—13/111 (11.7%)65/111 (58.6%)
Placebo/ Ixe 80 mg Q2W - Extended Treatment Period—6/46 (13%)20/46 (43.5%)
Placebo/ Ixe 80 mg Q4W - Extended Treatment Period—3/46 (6.5%)32/46 (69.6%)
Ixe 80 mg Q2W - Post Treatment Follow-Up Period—1/142 (0.7%)16/142 (11.3%)
Ixe 80 mg Q4W - Post Treatment Follow-Up Period—2/145 (1.4%)13/145 (9%)
PBO - Post Treatment Follow-Up Period—2/17 (11.8%)2/17 (11.8%)
Most frequent serious events
Showing 10 of 61
Most frequent serious events
EventIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Knee arthroplastySurgical and medical procedures0/1230/1220/1180/170/150/161/160/1070/1110/460/460/1420/1450/17
Postoperative wound infectionInfections and infestations0/1230/1220/1180/170/150/160/160/1070/1110/460/460/1420/1451/17
Postoperative wound complicationInjury, poisoning and procedural complications0/1230/1220/1180/170/150/160/160/1070/1110/460/460/1420/1451/17
PsoriasisSkin and subcutaneous tissue disorders0/1230/1220/1180/170/150/160/160/1070/1110/460/460/1420/1451/17
Cardio-respiratory arrestCardiac disorders0/1230/1220/1180/170/150/160/160/1070/1111/460/460/1420/1450/17
Basedow's diseaseEndocrine disorders0/1230/1220/1180/170/150/160/160/1070/1111/460/460/1420/1450/17
Abdominal painGastrointestinal disorders0/1230/1221/1180/170/150/160/160/1070/1110/461/460/1420/1450/17
Colitis ulcerativeGastrointestinal disorders0/1230/1220/1180/170/150/160/160/1070/1110/461/460/1420/1450/17
Inguinal herniaGastrointestinal disorders0/1230/1220/1180/170/150/160/160/1070/1111/460/460/1420/1450/17
NauseaGastrointestinal disorders0/1230/1220/1180/170/150/160/160/1070/1110/461/460/1420/1450/17
Most frequent other events
Showing 10 of 48
Most frequent other events
EventIxekizumab 80 mg Q2W (Ixe 80 mg Q2W)- Blinded Treatment PeriodIxekizumab 80 mg Q4W (Ixe 80 mg Q4W)- Blinded Treatment PeriodPlacebo (PBO) - Blinded Treatment PeriodIxe 80 mg Q2W - Blinded Treatment Period IRIxe 80 mg Q4W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q2W - Blinded Treatment Period IRPBO IR / Ixe 80 mg Q4W - Blinded Treatment Period IRIxe 80 mg Q2W / Ixe 80 mg Q2W - Extended Treatment PeriodIxe 80 mg Q4W / Ixe 80 mg Q4W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q2W - Extended Treatment PeriodPlacebo/ Ixe 80 mg Q4W - Extended Treatment PeriodIxe 80 mg Q2W - Post Treatment Follow-Up PeriodIxe 80 mg Q4W - Post Treatment Follow-Up PeriodPBO - Post Treatment Follow-Up Period
Upper respiratory tract infectionInfections and infestations12/12312/1229/1180/170/151/160/1620/10715/1114/468/462/1421/1450/17
NasopharyngitisInfections and infestations4/1239/1224/1180/171/150/160/1615/10720/1116/464/463/1425/1450/17
Benign prostatic hyperplasiaReproductive system and breast disorders1/500/630/560/50/90/100/91/461/561/243/200/640/720/9
SinusitisInfections and infestations5/1237/1222/1180/170/150/161/1610/10711/1114/466/463/1420/1450/17
Injection site erythemaGeneral disorders4/1233/1220/1181/170/152/160/161/1070/1110/460/460/1420/1450/17
Injection site reactionGeneral disorders15/1236/1221/1182/171/152/161/166/1072/1114/465/460/1420/1450/17
Injection site painGeneral disorders2/1231/1222/1182/170/151/160/163/1070/1111/461/460/1420/1450/17
Urinary tract infectionInfections and infestations4/1236/1223/1180/170/150/160/166/1077/1111/465/462/1420/1452/17
BronchitisInfections and infestations3/1231/1224/1180/170/150/161/1611/10711/1111/462/461/1420/1450/17
GastritisGastrointestinal disorders1/1230/1220/1180/170/150/160/161/1070/1110/464/460/1420/1450/17

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Mean51.5 ± 10.3952.6 ± 13.5751.7 ± 11.8551.9 ± 12.00
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Female625973194
Male566350169
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Hispanic or Latino11111335
Not Hispanic or Latino106109109324
Unknown or Not Reported1214
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
American Indian or Alaska Native0000
Asian77721
Native Hawaiian or Other Pacific Islander0101
Black or African American1113
White108111113332
More than one race2215
Unknown or Not Reported0011
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumab 80 mg Q4WIxekizumab 80 mg Q2WTotal
Czechia84820
United States606563188
Taiwan66719
Poland54514
Italy0011
United Kingdom56516
Australia2237
France66517
Germany11131236
Spain15161445
08

Study locations

109 sites
  • Rheumatology Associates PC
    Birmingham, Alabama 35205, United States
  • Arizona Arthritis & Rheumatology Research
    Glendale, Arizona 85304, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Mesa, Arizona 85210, United States
  • Arizona Arthritis & Rheumatology Research
    Phoenix, Arizona 85032, United States
  • Little Rock Diagnostic Clinic
    Little Rock, Arkansas 72205, United States
  • University of California - San Diego
    La Jolla, California 92093, United States
  • Purushotham & Akther Kotha MD Inc
    La Mesa, California 91942, United States
  • Stanford University Hospital
    Palo Alto, California 94304, United States
  • East Bay Rheumatology Medical Group
    San Leandro, California 94578, United States
  • Office: Dr Robin K Dore
    Tustin, California 92780, United States
  • Rheumatology Associates of South Florida
    Boca Raton, Florida 33486, United States
  • Jeffrey Alper MD Research
    Naples, Florida 34102, United States
  • Arthritis & Osteoporosis Treatment Center, PA
    Orange Park, Florida 32073, United States
  • Florida Medical Clinic PA
    Zephyrhills, Florida 33542-7505, United States
  • Diagnostic Rheumatology and Research
    Indianapolis, Indiana 46227, United States
  • Physicians Clinic of Iowa
    Cedar Rapids, Iowa 52403, United States
  • Heartland Research Associates
    Wichita, Kansas 67207, United States
  • Bluegrass Community Research. Inc
    Lexington, Kentucky 40504, United States
  • Johns Hopkins Arthritis Center
    Baltimore, Maryland 21224, United States
  • Klein and Associates MD, PA
    Cumberland, Maryland 21502, United States
  • Klein and Associates MD, PA
    Hagerstown, Maryland 21740, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Beals Institute PC
    Lansing, Michigan 48917, United States
  • North MS Medical Clinics, Inc.
    Tupelo, Mississippi 38801, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Glacier View Research Institute
    Kalispell, Montana 59901, United States
  • Physician Research Collaboration, LLC
    Lincoln, Nebraska 68516, United States
  • New Jersey Physicians
    Clifton, New Jersey 07012, United States
  • Atlantic Coastal Research
    Toms River, New Jersey 08755, United States
  • Arthritis, Rheumatic & Back Disease Associates
    Voorhees, New Jersey 08043, United States
  • Albuquerque Rehabilitation & Rheumatology, PC
    Albuquerque, New Mexico 87102, United States
  • The Center for Rheumatology
    Albany, New York 12203, United States
  • Weill Cornell Medical College
    Brooklyn, New York 11201, United States
  • Allergy Asthma Immunology of Rochester, AAIR Research Ctr
    Rochester, New York 14618, United States
  • Rheumatology Associates of Long Island
    Smithtown, New York 11787, United States
  • Arthritis and Osteoporosis Consultants of the Carolinas
    Charlotte, North Carolina 28207, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28210, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28602, United States
  • STAT Research
    Dayton, Ohio 45417, United States
  • Health Research Institute
    Oklahoma City, Oklahoma 73103, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • PMA Medical Specialists, LLC
    Limerick, Pennsylvania 19468, United States
  • Clinical Research Center of Reading, LLC
    Wyomissing, Pennsylvania 19610, United States
  • Pennsylvania Regional Center for Arthritis & Osteoarthritis
    Wyomissing, Pennsylvania 19610, United States
  • Methodist Healthcare
    Memphis, Tennessee 38104-3499, United States
  • Ramesh C. Gupta MD
    Memphis, Tennessee 38119, United States
  • Austin Rheumatology Research PA
    Austin, Texas 78705, United States
  • Austin Regional Clinic
    Austin, Texas 78731, United States
  • Arthritis Care & Diagnostic Center P.A.
    Dallas, Texas 75231, United States
  • Pioneer Research Solutions
    Houston, Texas 77008, United States
  • Houston Institute for Clinical Research
    Houston, Texas 77074, United States
  • Accurate Clinical Research
    Houston, Texas 77084, United States
  • Accurate Clinical Research
    League City, Texas 77573, United States
  • Arthritis & Osteoporosis Associates LLP
    Lubbock, Texas 79424, United States
  • Kadlec Clinic Rheumatology
    Kennewick, Washington 99336, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99204, United States
  • Rheumatology and Immunotherapy Center
    Franklin, Wisconsin 53132, United States
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Coast Joint Care
    Maroochydore, Queensland 4558, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • CCBR Czech Prague, s.r.o.
    Praha, 13000, Czechia
  • MEDICAL PLUS, s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • PV-MEDICAL s.r.o. Revmatologicka ambulance
    Zlin, 760 01, Czechia
  • Hôpital Trousseau, CHRU de Tours
    Chambray-lès-Tours, 37170, France
  • CHU de Montpellier-Hopital Arnaud de Villeneuve
    Montpellier Cedex 5, 34295, France
  • Chru De Nantes Hotel-Dieu
    Nantes Cedex 1, 44093, France
  • Hopital Cochin
    Paris CEDEX 14, 75679, France
  • Hopital Purpan
    Toulouse, 31059, France
  • CHU Brabois
    Vandoeuvre Les Nancy, 54511, France
  • Universitätsklinikum Heidelberg
    Heidelberg, Baden-Württemberg 69120, Germany
  • Universitätsklinikum Würzburg
    Würzburg, Bayern 97080, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Rheumazentrum Ruhrgebiet
    Herne, Nordrhein-Westfalen 44649, Germany
  • Krankenhaus Dresden-Friedrichstadt Städtisches Klinikum
    Dresden, Sachsen 01067, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen 01307, Germany
  • Universität Leipzig - Universitätsklinikum
    Leipzig, Sachsen 04103, Germany
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, Schleswig-Holstein 23538, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • HRF Hamburger Rheuma Forschungszentrum
    Hamburg, 20095, Germany
  • Istituto Ortopedico Gaetano Pini
    Milano, 20122, Italy
  • Azienda Ospedaliera - Universitaria Pisana
    Pisa, 56126, Italy
  • Malopolskie Centrum Medyczne S.C.
    Krakow, 30-510, Poland
  • Medica pro Familia Sp z o.o. S.K.A
    Krakow, 30002, Poland
  • AI Centrum Medyczne
    Poznan, 61-113, Poland
  • Medica pro Familia Sp z o.o. S.K.A
    Warszawa, 01-868, Poland
  • Rheuma Medicus Zakład Opieki Zdrowotnej
    Warszawa, 02-118, Poland
  • Hospital Infanta Luisa
    Sevilla, Andalucia 41007, Spain
  • Centro de Salud Mental Parc Tauli
    Sabadell, Barcelona 08208, Spain
  • Hospital Universitario Marques De Valdecilla
    Santander, Cantabria 39008, Spain
  • Hospital De Fuenlabrada
    Fuenlabrada, Madrid 28942, Spain
  • Hospital De Basurto
    Bilbao, Vizcaya 48013, Spain
  • Complexo Hospitalario Universitario A Coruña, CHUAC
    La Coruña, 15006, Spain
  • Hospital Regional Universitario de Málaga
    Malaga, 29009, Spain
  • Hospital Universitario Nuestra Señora de Valme
    Sevilla, 46014, Spain
  • Chi-Mei Hospital, Liouying
    Tainan City, Yongkang Dist, Taiwan
  • Chang Gung Memorial Hospital - Kaohsiung
    Kaohsiung City (r.o.c), 83301, Taiwan
  • Chung Shan Medical University Hospital
    Taichung City, 40201, Taiwan
  • China Medical University Hospital
    Taichung, 40447, Taiwan

Showing the first 100 of 109 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Eder L, Tony HP, Odhav S, Agirregoikoa EG, Korkosz M, Schwartzman S, Sprabery AT, Gellett AM, Park SY, Bertram CC, Ogdie A. Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials. Rheumatol Ther. 2022 Jun;9(3):919-933. doi: 10.1007/s40744-022-00445-w. Epub 2022 Apr 9. PubMed 35397092 ↗
  • Deodhar AA, Combe B, Accioly AP, Bolce R, Zhu D, Gellett AM, Sprabery AT, Burmester GR. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022 Jul;81(7):944-950. doi: 10.1136/annrheumdis-2021-222027. Epub 2022 Apr 7. PubMed 35393269 ↗
  • Combe B, Tsai TF, Huffstutter JE, Sprabery AT, Lin CY, Park SY, Kronbergs A, Hufford MM, Nash P. Ixekizumab, with or without concomitant methotrexate, improves signs and symptoms of PsA: week 52 results from Spirit-P1 and Spirit-P2 studies. Arthritis Res Ther. 2021 Jan 27;23(1):41. doi: 10.1186/s13075-020-02388-5. PubMed 33499913 ↗
  • Orbai AM, Gratacos J, Turkiewicz A, Hall S, Dokoupilova E, Combe B, Nash P, Gallo G, Bertram CC, Gellett AM, Sprabery AT, Birt J, Macpherson L, Geneus VJ, Constantin A. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2). Rheumatol Ther. 2021 Mar;8(1):199-217. doi: 10.1007/s40744-020-00261-0. Epub 2020 Dec 5. PubMed 33278016 ↗
  • Schweikert B, Malmberg C, Nunez M, Dilla T, Sapin C, Hartz S. Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain. BMJ Open. 2020 Aug 13;10(8):e032552. doi: 10.1136/bmjopen-2019-032552. PubMed 32792421 ↗
  • Combe B, Rahman P, Kameda H, Canete JD, Gallo G, Agada N, Xu W, Genovese MC. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis. Arthritis Res Ther. 2020 Jan 21;22(1):14. doi: 10.1186/s13075-020-2099-0. PubMed 31964419 ↗
  • Tillett W, Lin CY, Zbrozek A, Sprabery AT, Birt J. A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire. Rheumatol Ther. 2019 Sep;6(3):379-391. doi: 10.1007/s40744-019-0155-5. Epub 2019 Jun 1. PubMed 31154634 ↗
  • Coates LC, Orbai AM, Morita A, Benichou O, Kerr L, Adams DH, Shuler CL, Birt J, Helliwell PS. Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients' health-related quality of life and productivity. BMC Rheumatol. 2018 Aug 13;2:24. doi: 10.1186/s41927-018-0030-y. eCollection 2018. PubMed 30886974 ↗
  • Gladman DD, Orbai AM, Klitz U, Wei JC, Gallo G, Birt J, Rathmann S, Shrom D, Marzo-Ortega H. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Res Ther. 2019 Jan 29;21(1):38. doi: 10.1186/s13075-019-1831-0. PubMed 30696483 ↗
  • Genovese MC, Combe B, Kremer JM, Tsai TF, Behrens F, Adams DH, Lee C, Kerr L, Nash P. Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Rheumatology (Oxford). 2018 Nov 1;57(11):2001-2011. doi: 10.1093/rheumatology/key182. PubMed 30053162 ↗
  • Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. PubMed 28551073 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and european union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2014 to primary completion in Sep 2016, 20 months.

Results were first posted in Dec 2017, 1 year 3 months after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 20 months is below that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2014
First posted
Jan 28, 2015
StartActual
Dec 31, 2014
Primary completionActual
Sep 9, 2016
CompletionActual
Jun 26, 2019
Results first posted
Dec 14, 2017
Last update
Jul 1, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 1, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02349295
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
Dec 31, 2014
Primary completion
Sep 9, 2016
Completion
Jun 26, 2019
Results posted
Dec 14, 2017
Last update
Jul 1, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion